Synthorx, Inc.
https://synthorx.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Synthorx, Inc.
Sanofi Stays Bullish On Synthorx IL-2 Drug, But It’s Early Days
In an interview, oncology development exec Peter Adamson reiterated the company’s view that THOR-707 is best-in-class, but more data are needed to see where its efficacy stands amid the IL-2 herd.
Sanofi Grows Clinical Trials During Pandemic With Use Of Inhouse Clinical Supply Chain
Sanofi R&D head John Reed says company has kept 95% of patients on its nearly 400 clinical trials and started 59 studies. Company has also stepped up collaborations and closed acquisitions, integrating employees remotely.
Sanofi Hits M&A Trail Again To Buy UK's KyMab
Another UK biotech has been swallowed up by a big pharma with Sanofi acquiring the Cambridge-based firm in a deal that could be worth almost $1.5bn.
Sanofi Grapples With Pandemic, Growing Clinical Trials, Implementing Acquisitions
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Drug Discovery Tools
-
Drug Discovery Tools
- ADMET